As a key step in Bayer’s “In China, for Global” strategy, the Bayer E-Town Open Innovation Center officially opened in Beijing. The Center aims to foster deep integration among industry, academia, research, and entrepreneurship, creating an open ecosystem that connects China’s innovation with the globe.
Established in 2023 in Beijing E-Town’s BioPark, the Bayer E-Town Open Innovation Center is Bayer’s first innovation center in China. It will incubate local innovative biopharma companies, help bring China-developed drugs to global markets, and strengthen China’s full innovation value chain. By partnering with leading academic and clinical research institutions, the Center will also enhance basic research and clinical translation capabilities while driving data-enabled digital business innovation.
As the first outcome of this innovation system, Bayer Co.Lab welcomed two new resident companies at the Bayer E-Town Open Innovation Center: Suzhou Puhe BioPharma Co., Ltd and Beijing Youngen Technology Co., Ltd. Puhe BioPharma focuses on developing innovative small-molecule precision therapeutics and is collaborating with Bayer on an oral PRMT5 inhibitor targeting MTAP-deleted tumors. Youngen, a high-tech biopharmaceutical company dedicated to the development and translation of gene therapy products, will be supported by Bayer Co.Lab to explore the application potential of small nucleic acid drugs and accelerates the development of next-generation precision therapies.
